#	Pagina
attuale pagina	/open-h2020/projects/226736/index.html

Opendata, web and dolomites

DRTB-HDT SIGNED

STRATIFIED HOST-DIRECTED THERAPY FOR DRUG-RESISTANT TUBERCULOSIS: A RANDOMIZED CONTROLLED MULTI-CENTRE TRIAL

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

DRTB-HDT project word cloud

Explore the words cloud of the DRTB-HDT project. It provides you a very rough idea of what is the project "DRTB-HDT" about.

ground inflammation microbial 11050 began vs adhere host spirometry baseline endpoints conversion respectively reducing tolerated infection sites permanent candidates time culture treatments bronchiectasis efficacy prevent multidrug mozambique clinical centre co examine poorly disability hdt fibrosis majority reduce cure randomized tuberculosis africa lung arms resistant complementary cell adjunctive therapies rifampicin clinically 330 outcome metformin leave impairment preclinical anti inadequate hdts trial data germany morbidity enrolled cured 54 tb regimens national either health moldova closely global stable worldwide experimental armed successful estimates guidelines georgia quantitative romania risk radiodensity life primary radiographic capacity south ct outcomes receive magnified 2016 strategies public cc sputum poor shortcomings breaking function therapy treatment drug directed scan sub rif measured inducing mortality urgent patients standard requiring

Project "DRTB-HDT" data sheet

The following table provides information about the project.

Coordinator	SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT Organization address address: SOCINSTRASSE 57 city: Basel postcode: CH-4002 website: www.swisstph.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Switzerland [CH]
Total cost	9˙969˙012 €
EC max contribution	9˙969˙012 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2019-Two-Stage-RTD
Funding Scheme	RIA
Starting year	2020
Duration (year-month-day)	from 2020-01-01 to 2023-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT Organization address address: SOCINSTRASSE 57 city: Basel postcode: CH-4002 website: www.swisstph.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (Basel)	coordinator	1˙155˙060.00
2	THE AURUM INSTITUTE NPC THE AURUM INSTITUTE NPC Organization address address: THE RIDGE 29 QUEENS ROAD city: PARKTOWN JOHANNESBURG postcode: 2193 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ZA (PARKTOWN JOHANNESBURG)	participant	3˙200˙656.00
3	WITS HEALTH CONSORTIUM (PTY) LTD WITS HEALTH CONSORTIUM (PTY) LTD Organization address address: Princess of Wales Terrace, Parktown, 31 city: Johannesburg postcode: 2193 website: www.witshealth.co.za contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ZA (Johannesburg)	participant	1˙752˙440.00
4	Instituto Nacional de Saúde Instituto Nacional de Saúde Organization address address: Avenida Eduardo Mondlane 1008 city: Maputo postcode: n.a. website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	MZ (Maputo)	participant	868˙332.00
5	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 website: www.uni-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	808˙922.00
6	FORSCHUNGSZENTRUM BORSTEL FORSCHUNGSZENTRUM BORSTEL Organization address address: Parkallee 1-40 city: BORSTEL postcode: 23845 website: www.fz-borstel.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BORSTEL)	participant	753˙750.00
7	NATIONAL CENTER FOR TUBERCULOSIS AND LUNG DISEASES JSC NATIONAL CENTER FOR TUBERCULOSIS AND LUNG DISEASES JSC Organization address address: 8 ADJARA city: TBILISI postcode: 101 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	GE (TBILISI)	participant	618˙000.00
8	INSTITUTUL DE PNEUMOFTIZIOLOGIE MARIUS NASTA INSTITUTUL DE PNEUMOFTIZIOLOGIE MARIUS NASTA Organization address address: SOSEAUA VIILOR 90 SECTOR 5 city: BUCURESTI postcode: 50159 website: www.mariusnasta.ro contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	RO (BUCURESTI)	participant	353˙750.00
9	UNIVERSITEIT ANTWERPEN UNIVERSITEIT ANTWERPEN Organization address address: PRINSSTRAAT 13 city: ANTWERPEN postcode: 2000 website: www.ua.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (ANTWERPEN)	participant	275˙199.00
10	"INSTITUTIA MEDICO-SANITARA PUBLICA - INSTITUTUL DE FTIZIOPNEUMOLOGIE ""CHIRIL DRAGANIUC""" "INSTITUTIA MEDICO-SANITARA PUBLICA - INSTITUTUL DE FTIZIOPNEUMOLOGIE ""CHIRIL DRAGANIUC""" Organization address address: STRADA VIRNAV C 13 city: CHISINAU postcode: 2025 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	MD (CHISINAU)	participant	182˙901.00

Map

Project objective

Tuberculosis is a leading cause of morbidity and mortality worldwide. Current TB treatments are inadequate, requiring patients closely adhere to multi-drug regimens that are long, complex, and often poorly tolerated. These concerns are greatly magnified in rifampicin-resistant (RIF-R) TB, an urgent global and EU public health priority. WHO estimates that only 54% of patients who began RIF-R TB treatment in 2016 were cured. In addition to these well-recognized shortcomings, current TB treatments, particularly those for RIF-R TB, leave a majority of cured patients with permanent, clinically significant lung impairment and radiographic evidence of bronchiectasis and fibrosis. This project will determine if two adjunctive host-directed therapies (HDTs) can prevent these poor outcomes. 330 patients with RIF-R TB and baseline risk factors for poor outcome will be enrolled in a randomized, controlled, 3-armed multi-centre trial, with clinical sites in Germany, Romania, Moldova, Georgia, Mozambique, and South Africa. All patients will receive standard multidrug therapy according to national guidelines. Those patients randomized to the experimental arms will in addition receive either CC-11050 or metformin. These selected HDT candidates represent 2 complementary HDT strategies: reducing inflammation vs inducing host cell anti-microbial activity, respectively. Both candidates are supported by data from preclinical and clinical studies. Co-primary efficacy endpoints will examine effects on lung function (measured by spirometry) and infection (measured as time to stable sputum culture conversion). A sub-study will examine quantitative change in lung radiodensity by CT scan. If successful, this ground-breaking project will increase Europe’s capacity to control RIF-R-TB by developing new treatments that increase the likelihood of cure and reduce the risk of life-long disability.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DRTB-HDT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DRTB-HDT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More